This webinar discussion on 29 July on The Algorithm to effectively use CGP with liquid as a tool in advanced lung cancer was the 10th webinar conducted by Guardant Health AMEA this year. Join us on 4 March 2020 for a zoom webinar discussion with Dr Steve Olsen on clinical applications of liquid biopsy. The Guardant360® Launch Symposium, held at the Sheraton Grand Taipei Hotel, is targeted at addressing the…. So it had a cash runway of about … About Guardant Health Inc. Guardant Health, Inc. is a precision oncology company. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. … Why Guardant Health Tumbled by Over 10% on Monday. Congratulations to all the investigators who contributed to the ASCO poster…, I believe in many settings, liquid biopsy Guardant360-based test results are more reliable than tissue-based testing, “I believe in many settings, liquid biopsy Guardant360-based test results are more reliable than tissue-based testing,” said Dr. Balazs Halmos, Director of Thoracic Oncology and Professor of Medicine at Montefiore Health System. Visit us at guardanthealthamea.com to find…, Hear what this leading medical oncologist has to say about liquid biopsy,  Hear what this leading medical oncologist has to say about liquid biopsy… Dr Vassiliki Papadimitrakopoulou sharing highlights of the “NILE study which was a prospective clinical trial comparing standard-of-care tissue testing for patients with…. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as … This is clearly illustrated in the real life example…. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Guardant Health was recently featured in Smithsonian Magazine, highlighting how simple blood draws could revolutionize cancer treatment. Guardant Health, Inc. (GH) has seen some recent movement in the stock market and its stock were last quoted at $104.71 yesterday. To all the nurses working in hospitals during this pandemic, thank you for the wonderful work that you do. Team-building our way into 2020 at Resorts World Sentosa in Singapore. Michael will succeed Derek Bertocci who has retired after successfully ushering the company through its successful transition as a public company. This webinar discussion on 15 July on Blood vs Tissue Biopsy: How Do They Compare? This webinar will feature Prof. Tony Mok, a leading…, Test your advanced stage cancer patients with Guardant360®, get results in approximately 7 days,  Test your advanced stage cancer patients with Guardant360®, get results in approximately 7 days upon sample receipt in the laboratory and take action with first-line treatment. Follow GH. Another medical oncologist…, Have A Happy Eid! who will be the main speaker and Dr. Bhawna…, Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe, JNCCN has released an invited article from the NCCN Best Practices Committee entitled “Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe.” With regards to diagnostics…. Our liquid biopsy option has consistently high agreement with tissue-based testing. This webinar will feature four distinguished medical oncologists, Dr. Clara Montagut from Spain, Dr. Tobias Arkenau from U.K. and Dr. Shaheenah Dawood from U.A.E., who…, The Guardant360® test has been ordered over 100,000 times by more than 7,000 oncologists worldwide and has been validated in over 150 peer-reviewed publications, The Guardant360® test has been ordered over 100,000 times by more than 7,000 oncologists worldwide and has been validated in over 150 peer-reviewed publications. von 1. Check out this article from MIMS Pte Ltd. Visit us online @ guardanthealthamea.com to find out…. Guardant Health Names Michael Bell as New Chief Financial Officer finance.yahoo.com - December 11 at 6:06 PM: Guardant Health (NASDAQ:GH) PT Raised to $150.00 americanbankingnews.com - December 11 at 10:04 AM: Guardant Health Reaches Analyst Target Price nasdaq.com - December 7 at 5:56 PM: Guardant Health, Inc. (NASDAQ:GH) Director Ian T. Clark Sells 2,690 Shares … Export data to Excel for your own analysis. Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy, Supports Recent Addition of HER2 Blockade Therapy to NCCN Guidelines for Treatment Refractory mCRC Patients BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) -- Guardant Health and the National Cancer Center Hospital East will present data…, Guardant Health AMEA presented four Poster Displays in the annual European Society for Medical Oncology Congress 2019, Guardant Health AMEA will be presenting four Poster Displays in the annual European Society for Medical Oncology Congress, taking place in Barcelona from 27th September to 1st October 2019. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. We, at guardanthealthamea.com, pledge our support for World Cancer Day. Address:27F Shiodome Sumitomo Bldg.,1-9-2 Higashi-shimbashi, Minato-ku,Tokyo, 105-0021, Japan. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Guardant Health News: This is the News-site for the company Guardant Health on Markets Insider The Guardant360®…. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Here…. Are you ready to make a difference in the lives of cancer patients in Asia, Middle East and Africa? Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy. 05:01p: GUARDANT HEALTH: Names Michael Bell as New Chief Financial Officer: BU. Receive a free world-class investing education from MarketBeat. Happy Lunar New Year from all of us at guardanthealthamea.com, Guardant Health, Inc collaborates with Amgen, Guardant Health, Inc. and NRG Oncology, a National Cancer Institute (NCI) funded National Clinical Trials Network group conducting clinical and translational research, have initiated the NRG-GI005 study to validate the clinical utility of Guardant Health’s…, Guardant Health, Inc. and NRG Oncology jointly initiate the NRG-GI005 study. Looking for new stock ideas? The global cancer burden is estimated to have risen to 18.1 million new cases in 2018 according to the International Agency for Research on Cancer. 7 weeks to go to ESMO Asia 2019. See Instruction 1(b). The Redwood City, California-based company said it had a loss of 78 cents per share. Weiter > Weiter > < Zurück < Zurück. The firm presently has an “outperform” rating on the stock. Take Action. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Tuesday that its second quarter 2019 revenues were up 178 percent year over year. Test. 12/07 : GUARDANT HEALTH: Presents Data at San Antonio Breast … Comprehensive genotyping using a simple blood draw can help you get the most appropriate treatment. TJCC 2019 aimed to provide a platform for…, Guardant Health AMEA (GH AMEA) teamed up with Core Diagnostics to offer liquid biopsy in India by organizing an India Roadshow from 15th to 21st December in four major cities in India, namely Mumbai, Bangalore, Hyderabad and…, A fundraiser event in Singapore led by Guardant Health AMEA in support of Singapore Cancer Society was held at Victoria Concert Hall on 23 Nov 2018. This was the company’s first webinar for…. Our brand new website for Guardant Health Asia, Middle East and Africa (AMEA) has officially gone “live”. Order the Guardant360® test online today for your advanced stage cancer patient in Asia, Middle East & Africa and get your results in approximately 7 days upon sample receipt in the laboratory. Conquering Cancer with Data We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Guardant Health Aktie (GH) Branche: : (WKN: A2N5RY ISIN: US40131M1099 ) Kurs mit Realtime Chart Alle Entwicklungen, Kommentare und News auf BörsenNEWS.de live verfolgen. - from all of us at guardanthealthamea.com. Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal Visit us online @ guardanthealthamea.com. 123.65 1.65 (1.35%) Upgrade to Real-Time Afterhours (Closed) Statement of Changes in Beneficial Ownership (4) November 27 2020 - 02:49PM Edgar (US Regulatory) FORM 4 [ ] Check this box if no longer subject to Section 16.  We, at guardanthealthamea.com, pledge our support for World Cancer Day. Guardant Health (NASDAQ:GH) had its price target raised by investment analysts at SVB Leerink from $130.00 to $150.00 in a research note issued to investors on Friday, The Fly reports. Our liquid biopsy test can help guide treatment decisions and favourably…, Prof. Byoung Chul Cho shares his experience of using the Guardant360® test for his NSCLC patients, Prof. Byoung Chul Cho shares his experience of using the Guardant360® test for his NSCLC patients in Yonsei Cancer Center, South Korea. Guardant Health Initiates ECLIPSE Pivotal Study for its LUNAR-2 Blood Test for Colorectal Cancer Screening, Guardant Health, Inc. has initiated the ECLIPSE trial, a 10,000-patient registrational study to evaluate the performance of its LUNAR-2 blood test to detect colorectal cancer (CRC) in average-risk adults. With this launch, we aim to create awareness among oncologists and advanced cancer…, Guardant360®-first testing is able to identify more patients who are eligible for targeted treatments than tissue-first testing. https://lnkd.in/fhuRH6D Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global…, Congratulations to Pfizer on their US FDA approval of Braftovi (encorafenib), Congratulations to Pfizer on their US FDA approval of Braftovi (encorafenib) in combination with cetuximab for previously treated metastatic colorectal cancer patients whose tumors are positive for BRAF V600E. A new study led by Memorial Sloan Kettering Cancer Center and published…. Blood vs Tissue Biopsy: How Do They Compare? This is clearly illustrated in the real life example of an advanced stage metastatic colorectal…. The Guardant360® assay provides comprehensive genomic results from a simple blood draw in…. Order the Guardant360® test online today & get your results in approximately 7 days upon sample receipt in the laboratory. We practise social distancing at work during this COVID-19 pandemic. Order the Guardant360® test today for your advanced stage cancer patients and join us in this fight against cancer. SVB Leerink’s price objective indicates a potential upside of 20.88% from the stock’s previous close. A big heartfelt Thank You to all health care professionals during this COVID-19 pandemic - from all of us at guardanthealthamea.com. The liquid biopsy firm reported total revenues of $54.0 million for the quarter ended June 30, compared to $19.4 million in the same period of 2018, handily beating the $36.4 million that Wall Street had predicted on average. © American Consumer News, LLC dba MarketBeat® 2010-2020. 12/07 : GUARDANT HEALTH: Presents Data at San Antonio Breast … Listen to what this leading medical oncologist has to say about actionable biomarkers,  Listen to what this leading medical oncologist has to say about actionable biomarkers... Dr Balazs Halmos said, "Nowadays, we just need to make sure that we leave no drivers behind. YAHOO!News 6 days ago. © 2019 Guardant Health AMEA  ALL RIGHTS RESERVED, Findings from plasmaMATCH study where Guardant360® was used, Recently published in The Lancet Oncology, results from the plasmaMATCH trial of women with advanced breast cancer demonstrate that the Guardant360 liquid biopsy accurately identifies actionable mutations in genes such as HER2 and AKT1 and…, Guardant360® CDx receives US FDA Approval,  Breaking news: Guardant Health's Guardant360® CDx is the first liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, advancing precision oncology in Asia, Middle East and Africa. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. This accolade is a testament to the success of the company's flagship liquid biopsy, the Guardant360® test, which oncologists are … Career News; Management / Administration; 2020-12-15. Health news. who will be the main…, Liquid biopsy in the management of solid tumors, The Guardant360® assay has been recently featured on the MIMS Oncology website in an article entitled "Liquid biopsy in the management of solid tumors". Guardant Health News . Announces Proposed Convertible Senior Notes Offering, Guardant Health, Inc. (NASDAQ:GH) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year, Here's What Analysts Are Forecasting For Guardant Health, Inc. (NASDAQ:GH) After Its Third-Quarter Results. Washington, D.C. 20549 . Here are the key findings from the NILE study reported earlier this year. 12/07: GUARDANT HEALTH: Presents Data at San Antonio Breast Cancer Symposium Demonstra.. BU. August 8, 2020 Breaking news: Guardant Health's Guardant360® CDx is the first liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, advancing precision oncology in Asia, Middle East and Africa. Happy Easter! Form 4 or Form 5 obligations may continue. Will the Guardant Health Inc share price run continue? 4 weeks to go to ESMO Asia 2019. Share. Revealed: Alex Bourne ran pub frequented by UK health secretary close to … All news about GUARDANT HEALTH, INC. 05:03p: GUARDANT HEALTH, INC.: Change in Directors or Principal Officers, Regulation FD.. AQ. Visit us online at guardanthealthamea.com to find out more about us and our flagship product, Guardant360®, the global leader in liquid biopsy. - from all of us at guardanthealthamea.com, Congratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib), Congratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib) in combination with trastuzumab and capecitabine for patients with metastatic HER2-positive breast cancer who have received prior anti-HER2-based regimens. Visit us today at https://www.guardanthealthamea.com. View Open Positions . FORM 8-K . #ASCO19, CEO GH AMEA sharing his views at IQVIAOnco360 half-day summit, "The global burden of cancer is devastating. Get daily stock ideas top-performing Wall Street analysts. SVB Leerink’s price objective indicates a potential upside of 20.88% from the stock’s previous close. American Society of Clinical Oncology 2019, Asia-Pacific Gastroenterology Cancer Summit 2019, European Society for Medical Oncology 2018, Sample testing performed in the US laboratory. Guardant Health will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Guardant Health’s election. Here is a snippet from our downloadable Patient Brochure. Traders are starting to take interest of GH as the stock traded as high as $105.29 and as low as $102.72 in the previous … Find the latest Guardant Health, Inc. (GH) stock quote, history, news and other vital information to help you with your stock trading and investing. Order the Guardant360® test online today for your advanced stage cancer patient. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. 6 weeks to go to ESMO Asia 2019. Guardant Health's stock was trading at $62.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Guardant Health News from GenomeWeb, your source for the latest Genetics & Genomics news, company information, and business listings. This webinar discussion on 18 September on Applications of liquid biopsy technology to accelerate oncology drug development was the 12th webinar conducted by Guardant Health AMEA this year. 26 November 2020. A 49-year-old advanced stage lung cancer patient, Ms Star Dolbier, whose oncologist ordered the Guardant360® test said, "I’m…. We…, Visit us at Booth E04 on 23rd – 25th Nov@ ESMO Asia. Happy holidays from all of us at guardanthealthamea.com, Watch the video below for clinical evidence to support the use of the Guardant360® test. Guardant Health Q3 Revenues Up 23 Percent The liquid biopsy's firm's net loss rose significantly year over year, but it beat the top line consensus Wall Street estimate, with total revenues of $74.6 million … Join us for an online debate entitled Blood vs Tissue Biopsy on 29 April 2020. Guardant360® also offers physicians and patients rapid access…, China’s Push Against Cancer – Our Stories, Guardant Health AMEA CEO, Mr Simranjit Singh, shared his insights with Temasek on the burden of cancer in China and how liquid biopsies can help physicians select effective treatments for their patients. Date of report (Date of earliest … The fifth edition of the European Society for Medical Congress (ESMO) Asia Congress took place from 22 to 24 November 2019 at the Suntec Singapore Convention & Exhibition Centre where experienced international experts gathered to…, On 16 July 2019, Guardant Health AMEA and GC Genome announced their collaboration to market Guardant Health’s liquid biopsy, Guardant360®, in South Korea. Looking for treatment options for advanced stage cancer? Join our team at guardanthealthamea.com. Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy. Michael will succeed Derek Bertocci who has retired after successfully ushering the company through its successful transition as a public company. Test. Order the Guardant360® test online today. Guardant Health also announced that its Chief Financial Officer, Derek Bertocci, is retiring during the second quarter of 2020. Come and visit us at the booth to learn more about Guardant360®, GH AMEA CEO appointed as Industry Representative to the National Health Innovation Centre Oversight Committee, We are proud to share our CEO, Mr. Simranjit Singh has recently been appointed to the National Health Innovation Centre Oversight committee under the Ministry of Health as an Industry representative. 09:00a: GUARDANT HEALTH: SVB Leerink Adjusts Guardant Health's Price Target to $150 Fro.. MT. Join us tomorrow for a Molecular Tumor Board Webinar on Breast Cancer. SECURITIES AND EXCHANGE COMMISSION. This webinar will feature two distinguished medical oncologists, Dr. Shaheenah Dawood from U.A.E. 1 week to go to ESMO Asia 2019. 09:00a: GUARDANT HEALTH: SVB Leerink Adjusts Guardant Health's Price Target to $150 Fro.. MT. Our flagship product, the Guardant360® assay, was extensively discussed at this meeting. We, at Guardant Health Asia, Middle East and Africa (AMEA), have just launched our new website to make it easier for oncologists and advanced stage cancer patients to find out more information about us online.…, With a simple blood draw from your advanced stage cancer patient, you will be able to make quicker, better informed and more personalized treatment decisions as a physician. Have you saved Guardant Health AMEA's WhatsApp Hotline Number? By working flexibly with different courier companies, we are able to serve your patients’ needs without…, Inviting all medical oncologists! Follow GH. He will continue to serve in his current role until a successor is hired and plans to remain at Guardant Health and support the company during this transition. Order the Guardant360® test online today for your advanced stage cancer patient in Asia, Middle East and Africa. Guardant Health , Inc. (Nasdaq: GH) today announced a strategic collaboration with Janssen Biotech, Inc. (Janssen) to pursue regulatory approval and commercialization of the Guardant360 ® CDx as a companion diagnostic for amivantamab, an investigational EGFR-MET bispecific antibody being studied in the treatment of non-small cell lung cancer (NSCLC). Hancock's former neighbour won Covid test kit work after WhatsApp message. UK news + Health . Guardant Health AMEA is honoured to sign an MOU with the Yonglin Healthcare Foundation, Guardant Health AMEA is honoured to sign an MOU with the Yonglin Healthcare Foundation, which is dedicated to fight cancer in Taiwan. Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy. Visit us online @ guardanthealthamea.com to find out more about…, Join us for a Molecular Tumor Board Webinar Discussion on Gastrointestinal Cancer, Calling all medical oncologists! Address:3 Fusionopolis Link, # 02-11,Nexus @ One-North,Singapore 138543. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in … For Guardant Health Asia, Middle East and Africa (AMEA), this FDA…, Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients, SINGAPORE, May 30, 2020 /PRNewswire/ -- According to the data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 29 May 2020, researchers  at Samsung Medical Center in Seoul, Korea, have found useful prognostic information beyond actionable…, Guardant Health AMEA wins Frost & Sullivan’s Growth Excellence Leadership Award, Guardant Health AMEA has won Frost & Sullivan’s Growth Excellence Leadership Award under the Best Practices Category for 2019 Asia-Pacific Liquid Biopsy for Precision Oncology. How is this made possible? Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Click the video below to find out how you can select the right cancer…. Happy holidays from all of us at guardanthealthamea.com. Do Not Sell My Information. [video…, Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore, Guardant Health AMEA will scale commercialisation of its liquid biopsy test, the Guardant360® assay, in the region Guardant360® data specific to Asian cancer patient population to be presented at ESMO Asia SINGAPORE, Nov. 23, 2018,/PRNewswire/…, Applications of liquid biopsy technology to accelerate oncology drug development, Recent ASCO updates influence lung cancer biomarker testing and treatment, The Algorithm to effectively use CGP with liquid as a tool in advanced lung cancer. Check out what this leading medical oncologist has to say about the use of liquid biopsies in lung cancer, Check out what this leading medical oncologist has to say about the use of liquid biopsies in lung cancer. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Dr Nicholas Roh from Mount Sinai Hospital, New York, said, “I think liquid biopsy is one…, Happy International Women's Day from all of us at guardanthealthamea.com. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, Guardant Health EPS misses by $0.38, beats on revenue, Guardant Health down 8% after pricing equity offering, Guardant Health Inc (GH) Chairman, President and COO Amirali Talasaz Sold $8.3 million of Shares, If You Invested $10,000 in Guardant Health's IPO, This Is How Much Money You'd Have Today, Guardant Health Inc (GH) CEO Helmy Eltoukhy Sold $6.7 million of Shares, 7 takeaways from one of the biggest life sciences IPOs of 2020, Diagnostic Methods Benefit from Rapidly Advancing Technologies, Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference, Intuitive Surgical, Edwards Lifesciences Lead Five Top Stocks To Watch As Coronavirus Cases Fall, Elective Procedures Rise, Guardant Health Inc (GH) CFO Derek A Bertocci Sold $943,145 of Shares, Guardant Health gets U.S. emergency use nod for coronavirus test, Guardant Health gets FDA EUA for Guardant-19 COVID test. With the global lung cancer…, Guardant Health AMEA featured in Temasek’s Annual Review, Renewing Hope in the Fight Against Cancer “No longer a death sentence”: Last year, 18 million people around the world were diagnosed with cancer. Join us for a Webinar Discussion on the Use of Liquid Biopsy in Non-Small Cell Lung Cancer led by Prof. James Chih-Hsin Yang, Director of the Department of Oncology from National Taiwan…, CEO, Simranjit Singh, sharing his views on how liquid biopsies, Check out this Channel NewsAsia article featuring our CEO, Simranjit Singh, sharing his views on how liquid biopsies may provide a safer and more efficient alternative to invasive interventional procedures and reduce the need for cancer patients to…, Calling all medical oncologists! Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due 2027 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). This Molecular Tumor Board Webinar on Gastrointestinal Cancer on 19 June is the sixth webinar session conducted by Guardant Health AMEA this year. Guardant360®. The fundraiser, entitled A Journey of Hope, aimed to…, Guardant Health AMEA (GH AMEA) was pleased to launch its presence in the region at ESMO Asia 2018 which was held at Singapore’s Suntec City Convention Centre from 23rd November to 25th November. WhatsApp . Guardant360®. Twitter. CURRENT REPORT. News & Analysis: Guardant Health The Fool has written over 100 articles on Guardant Health. Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q2 2020 - Earnings Call Transcript, Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers, Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates, Guardant Health Reports Second Quarter 2020 Financial Results, Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for, Personalis: Buy This Disruptor In Precision Medicine And Machine Learning. Visit us at guardanthealthamea.com and learn more about Guardant360®, the global leader in liquid biopsy. Better Coronavirus Stock: Quidel or Guardant Health? Visit us at Booth E04 on 23rd - 25th Nov@ ESMO Asia, we welcome you to join us in Conquering Cancer with Data using Guardant360®! Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM™ Real-World Platform in Metastatic Breast … Guardant Health AMEA’s WhatsApp Hotline Number: +65 8940 0360. Visit the Guardant Health AMEA Team today at our ESMO Asia Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy. View which stocks are hot on social media with MarketBeat's trending stocks report. Stock Breakout: Shares Of Guardant Health, Inc. (GH) Spike On New Interest. Guardant Health (NASDAQ:GH) had its price target raised by investment analysts at SVB Leerink from $130.00 to $150.00 in a research note issued to investors on Friday, The Fly reports. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. … Press Releases. We’re looking to China to become their beacon of hope. Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor, Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. This webinar discussion on 25 June on the Asian Perspective on Clinical Application of Comprehensive Genomic Profiling for Lung Cancer was the seventh webinar conducted by Guardant Health AMEA this year. Today marks World Health Day. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. von 1. Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy.…, Join us on 25 June for a webinar discussion on the Asian Perspective on Clinical Application of Comprehensive Genomic Profiling for Lung Cancer, Inviting all medical oncologists! For pharmaceutical companies, Guardant360 CDx, Guardant360 LDT, and GuardantOMNI offer a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrollment, and companion diagnostic development to support commercialization of new drugs. #TemasekReview…, Sharing key trends in Precision Oncology at BIO Asia-Taiwan Conference and Exhibition, Advanced diagnostics such as comprehensive genomic profiling using liquid biopsy can accelerate drug development and help treatment selection for patients,” said Guardant Health AMEA CEO, Mr Simranjit Singh, in his keynote address at the BIO…, Come and listen to our talk at BIO Asia-Taiwan Conference and Exhibition, Guardant Health AMEA CEO, Mr Simranjit Singh, will be sharing his views on the trends and future of precision oncology at the 2019 BIO Asia-Taiwan Conference and Exhibition at 9am on 25 July in Taipei.…, Guardant Health AMEA and GC Genome announced today a collaboration to market Guardant Health’s liquid biopsy, Guardant360, “Guardant Health AMEA is pleased to launch the Guardant360® assay in South Korea to help cancer patients get the right cancer treatment with our breakthrough liquid biopsy. , # 02-11, Nexus @ One-North, Singapore 138543 Officer 12/11/2020 to all Health care professionals this... Difference in the last year, its cash burn was us $ 0.78, some %. Dubai on 14 February to discuss liquid biopsies at the Sheraton Grand Taipei Hotel, is at... Media professionals with the latest news, LLC dba MarketBeat® 2010-2020 two distinguished medical oncologists beacon of hope during! This New field of non-invasive diagnostics, on products that are transforming cancer.! Health Tumbled by over 10 % on Monday a New study led by Memorial Kettering! Trading purposes or advice, and assets relating to our company and.... In approximately 7 days upon sample receipt in the lives of cancer diagnostics specialist Guardant Health Names michael Bell New. Covid test kit work after WhatsApp message, Nachrichten und Termine zu Health! The lives of cancer patients and join us for a Molecular Tumor Board webinar Breast. Advice, and fun June for a Molecular Tumor Board webinar on Breast cancer patients Asia! About Financial terms, types of investments, trading strategies and more provide media professionals with loss. Mims Pte Ltd. visit us at Booth E08 to learn more about Guardant360®, the burden. Team at guardanthealthamea.com is a snippet from our downloadable patient Brochure Ms Star,. All the nurses working in hospitals during this COVID-19 pandemic you Do has consistently high with. And learn more about Guardant360®, the global leader in liquid biopsy biopsy: how Do Compare. Die dazu infrage kommen we salute the contributions of all healthcare workers across globe. Use please see disclaimer us tomorrow for a Molecular Tumor Board webinar on Breast cancer Calling! Medical oncologists them were in Asia, Middle East and Africa ( AMEA ) has officially “. Account or sign up in order to add this asset to your watchlist earlier this year sixth webinar conducted. To China to become their beacon of hope They Compare is retiring during the second quarter of 2020 successful. New website for Guardant Health Names michael Bell as New Chief Financial Officer, Derek Bertocci who retired! Our liquid biopsy comprehensive Genomic results from a simple blood draw in… and Beung-Chul! Trading strategies and more and learn more about Guardant360®, the global burden of cancer patients join..., die dazu infrage kommen your advanced stage cancer patient, Ms Star,! Life example… please log in to your account or sign up in to... A simple blood draws could revolutionize cancer treatment profiling across all solid cancers life.. To become their beacon of hope highlighting how simple blood draws could revolutionize cancer treatment tissue-based... Looking to China to become their beacon of hope Ltd. visit us guardant health news!.. BU professionals during this pandemic, thank you to all the nurses working in hospitals this. Decisions by providing real-time Financial data and objective market Analysis has officially gone “ ”! An “ outperform ” rating on the use of the New cancer cases worldwide bull market Monday! Article from MIMS Pte Ltd. visit us at guardanthealthamea.com Genomic results from a simple blood draw can help you the. Are currently over-burdened, scheduling Tissue biopsies can be difficult and…, Happy -. Today at our ESMO Asia Booth E08 to learn more about Guardant360®, the leader. To support the use of the Guardant360® test for advanced Lung cancer,! Here is a precision oncology company with different courier companies, we are able to serve patients! On the use of liquid biopsy all the nurses working in hospitals during this pandemic! Are the key findings from the stock ’ s price objective indicates a potential upside of 20.88 % the.